Articles related to CLINICAL COVID

Many studies have a high risk of bias and significant heterogeneity, implying that results should be interpreted with caution. Nonetheless, most estimates of symptom change for general mental health, anxiety symptoms, and depression symptoms were close to zero and not statistically significant, and significant changes were of minimal to minor magnitudes. In all domains, women or female participants experienced minor negative changes.

Patients with long COVID may present in primary care with symptoms of palpitations from tachycardia triggered by standing or even limited exertion. Palpitations can be accompanied by other autonomic nervous symptom-associated symptoms such as dizziness, breathlessness, chest pain, sweating, bloating, and fatigue, and patients can find these symptoms debilitating.

Reports on the Vaccine Safety Datalink flagged the need to investigate a potential increased risk those 65 years of age and older, for ischemic stroke in the first 21 days after receiving the bivalent Pfizer-BioNTech booster. FDA has parallel monitoring systems to confirm or fail to validate a safety signal. In this case, those other systems did not confirm the Vaccine Safety Datalink flag.

In this extensive survey, patients with hematologic malignancies who have breakthrough COVID-19 have approximately 9% reduced mortality rate than they did before vaccination. Patients who received monoclonal antibodies, either alone or in conjunction with antivirals, had superior clinical results.

We can better understand outcomes in patients with a variety of ages, ethnicities, comorbidities, and exposures by using observational data. It can be challenging or even impossible to disentangle the diverse effects of dynamic elements like vaccination rates, patient behaviors, and COVID-19 pathogenicity. Randomized controlled trials involving blood cancer patients are required to fully assess the impact of COVID-19 therapies. The impact of both bivalent vaccines and prophylactic monoclonal antibodies, as well as ways to assure equitable distribution of COVID-19 vaccines and therapies, will all be determined by future study. Some of those studies must involve people who have hematologic malignancies.

The findings of this study are similar to results from in small human post-mortem study and could provide a pathological explanation for the subjective complaint of long-COVID “brain fog.” Using a mouse model to explore how mild respiratory infections with COVID could lead to neuroinflammation and subsequent brain damage, investigators found signs of central neuroinflammation after clearance of the virus. There is an accompanying case presentation.